A Phase I/II, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Pediatrics with Locally Advanced or Metastatic Solid or Primary CNS Tumors and/or who Have No Satisfactory Treatment Options
This Study is
No Longer Enrolling
Details
Age
Child
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Study ID
Protocol Number: 16-0749
More information available at ClinicalTrials.gov: NCT02650401
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers